These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 11418314

  • 1. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine.
    Stein R, Govindan SV, Chen S, Reed L, Spiegelman H, Griffiths GL, Hansen HJ, Goldenberg DM.
    Crit Rev Oncol Hematol; 2001; 39(1-2):173-80. PubMed ID: 11418314
    [Abstract] [Full Text] [Related]

  • 2. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
    Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, Hansen HJ, Goldenberg DM.
    J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
    [Abstract] [Full Text] [Related]

  • 6. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft.
    Stein R, Chen S, Haim S, Goldenberg DM.
    Cancer; 1997 Dec 15; 80(12 Suppl):2636-41. PubMed ID: 9406718
    [Abstract] [Full Text] [Related]

  • 7. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
    Stein R, Govindan SV, Hayes M, Griffiths GL, Hansen HJ, Horak ID, Goldenberg DM.
    Clin Cancer Res; 2005 Apr 01; 11(7):2727-34. PubMed ID: 15814655
    [Abstract] [Full Text] [Related]

  • 8. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small-cell carcinoma of the lung.
    Stein R, Goldenberg DM, Thorpe SR, Mattes MJ.
    J Nucl Med; 1997 Mar 01; 38(3):391-5. PubMed ID: 9074526
    [Abstract] [Full Text] [Related]

  • 9. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors.
    Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ.
    Cancer Res; 1995 Jul 15; 55(14):3132-9. PubMed ID: 7606734
    [Abstract] [Full Text] [Related]

  • 10. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
    Stein R, Blumenthal R, Sharkey RM, Goldenberg DM.
    Cancer; 1994 Feb 01; 73(3 Suppl):816-23. PubMed ID: 8306265
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer.
    Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5857s-5863s. PubMed ID: 7493360
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM, Béhé M, Löhr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, Becker W.
    Eur J Nucl Med; 2000 Jul 01; 27(7):753-65. PubMed ID: 10952487
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 16. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R, Juweid M, Mattes MJ, Goldenberg DM.
    Cancer Biother Radiopharm; 1999 Feb 01; 14(1):37-47. PubMed ID: 10850286
    [Abstract] [Full Text] [Related]

  • 17. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith R.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [Abstract] [Full Text] [Related]

  • 18. Radioimmunotherapy of human head and neck squamous cell carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG.
    Gerretsen M, Schrijvers AH, van Walsum M, Braakhuis BJ, Quak JJ, Meijer CJ, Snow GB, van Dongen GA.
    Br J Cancer; 1992 Sep 01; 66(3):496-502. PubMed ID: 1520586
    [Abstract] [Full Text] [Related]

  • 19. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, Goldenberg DM.
    Cancer Res; 1992 Nov 01; 52(21):6036-44. PubMed ID: 1394228
    [Abstract] [Full Text] [Related]

  • 20. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.